Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Chinese Patent Office
Citi
Deloitte
Argus Health
Colorcon
UBS
US Department of Justice
Harvard Business School

Generated: July 15, 2018

DrugPatentWatch Database Preview

Insulin lispro protamine recombinant; insulin lispro recombinant - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for insulin lispro protamine recombinant; insulin lispro recombinant and what is the scope of insulin lispro protamine recombinant; insulin lispro recombinant patent protection?

Insulin lispro protamine recombinant; insulin lispro recombinant
is the generic ingredient in six branded drugs marketed by Lilly and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Insulin lispro protamine recombinant; insulin lispro recombinant has twelve patent family members in nine countries.

There are thirty-nine drug master file entries for insulin lispro protamine recombinant; insulin lispro recombinant. Two suppliers are listed for this compound.
Summary for insulin lispro protamine recombinant; insulin lispro recombinant
International Patents:12
US Patents:1
Tradenames:6
Applicants:1
NDAs:2
Drug Master File Entries: 39
Suppliers / Packagers: 2
Clinical Trials: 9
DailyMed Link:insulin lispro protamine recombinant; insulin lispro recombinant at DailyMed
Pharmacology for insulin lispro protamine recombinant; insulin lispro recombinant
Ingredient-typeInsulin
Drug ClassInsulin Analog

US Patents and Regulatory Information for insulin lispro protamine recombinant; insulin lispro recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly HUMALOG MIX 75/25 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-002 Sep 6, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly HUMALOG MIX 50/50 PEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-003 Dec 22, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for insulin lispro protamine recombinant; insulin lispro recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG MIX 75/25 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021017-001 Dec 22, 1999 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for insulin lispro protamine recombinant; insulin lispro recombinant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,427,275 Medication dispensing apparatus with triple screw threads for mechanical advantage ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for insulin lispro protamine recombinant; insulin lispro recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0596 Netherlands ➤ Sign Up PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
2017 00013 Denmark ➤ Sign Up PRODUCT NAME: KOMBINATION AF INSULIN DEGLUDEC OG LIRAGLUTID; NAT. REG. NO/DATE: EU/1/14/947 20140922; FIRST REG. NO/DATE: CH 65041 20140912
C0085 France ➤ Sign Up PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
C/GB00/027 United Kingdom ➤ Sign Up PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Express Scripts
Cantor Fitzgerald
Accenture
Medtronic
Fish and Richardson
Cipla
UBS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.